Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Therapeutic Approaches for the Treatment of Cerebral-Neurovascular Diseases"'
Publikováno v:
Clinical and Applied Thrombosis/Hemostasis
Clinical and Applied Thrombosis/Hemostasis, Vol 27 (2021)
Clinical and Applied Thrombosis/Hemostasis, Vol 27 (2021)
Early catheter-directed thrombolysis (CDT) for lower extremity deep vein thrombosis (LEDVT) can reduce post-thrombotic morbidity and the AngioJet thrombectomy is a new therapy that can be selected for the treatment of LEDVT. We performed a systematic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::50a2e04ce2c65a304f7b2944ef441f43
https://pubmed.ncbi.nlm.nih.gov/33813903
https://pubmed.ncbi.nlm.nih.gov/33813903
Publikováno v:
Clinical and Applied Thrombosis/Hemostasis
Clinical and Applied Thrombosis/Hemostasis, Vol 27 (2021)
Clinical and Applied Thrombosis/Hemostasis, Vol 27 (2021)
Antiphospholipid syndrome (APS) with cerebral venous sinus thrombosis (CVST) is a relatively rare phenomenon, and this observational study aimed to investigate the clinical characteristics of APS patients complicated with CVST. We retrospectively inv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f11cd4219a64a1bae48ed0e770bf751d
http://europepmc.org/articles/PMC8058809
http://europepmc.org/articles/PMC8058809
Autor:
Steven K. Feske, Charlene Ong, Galen V. Henderson, Eva Rybak, Patricia Krause, Megan E Barra, Sarah E Culbreth, Katelyn W. Sylvester
Publikováno v:
Clinical and Applied Thrombosis/Hemostasis, Vol 26 (2020)
Clinical and Applied Thrombosis/Hemostasis
Clinical and Applied Thrombosis/Hemostasis
In patients with ischemic stroke who receive systemic recombinant tissue plasminogen activator (rt-PA), the risk of secondary hemorrhage is 1-7%. Fibrinogen supplementation with cryoprecipitate is recommended in patients with rt-PA-associated symptom
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4ea52f8f4eeda2d092379f669d261271
https://doaj.org/article/982e1705b0f84bb58a2f011c5b72978f
https://doaj.org/article/982e1705b0f84bb58a2f011c5b72978f
Publikováno v:
Clinical and Applied Thrombosis/Hemostasis, Vol 26 (2020)
Clinical and Applied Thrombosis/Hemostasis
Clinical and Applied Thrombosis/Hemostasis
Background: Specific clinical risk factors linked to transient ischemic attack (TIA) could affect functional ambulatory outcome following thrombolytic therapy in patients having ischemic stroke with a prior TIA (TIA-ischemic stroke). This issue was i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2c87356b9b45a7f472b8cdb60f01a9f6
https://doaj.org/article/59204895ba7f46fc8f7d38902e2f12cf
https://doaj.org/article/59204895ba7f46fc8f7d38902e2f12cf